Johnson & Johnson: brands it owns and its ownership tree
Johnson & Johnson (NYSE: JNJ) is a publicly listed company headquartered in New Brunswick, New Jersey, United States that owns 8 consumer brands, and has 1 recorded transaction.[1][2]
Johnson & Johnson was founded in 1886 to make sterile surgical dressings. It separated its consumer health business as Kenvue in 2023 and is now a pharmaceutical and medical technology company, so the household brands people associate with it are no longer owned by it.
What Johnson & Johnson's annual report says about its business
Read from Johnson & Johnson's latest annual filing[1]. Each line gives the sentence the filing uses, copied word for word.
Segments the filing names
Innovative Medicine, MedTech: The Company is organized into two business segments: Innovative Medicine and MedTech.
Acquisitions and disposals named in the filing
Acquired: Intra-Cellular Therapies, Inc. (April 2, 2025), $14.5 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.5 billion which closed on April 2, 2025, and for general corporate purposes.
Acquired: NM26 bispecific antibody (fiscal year 2024), $ 1.25 billion. For all years presented, there was no individual project that represented greater than 5 % of the total annual consolidated research and development expense other than the acquired in-process research & development expense of $ 1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.
Acquired: V-Wave (2024), $0.5 billion. Acquired in-process research & development expense of $0.5 billion from the V-Wave acquisition and a Laminar milestone of $0.3 billion in the MedTech business in 2024
Johnson & Johnson in numbers
Johnson & Johnson owns 8 consumer brands tracked here across 1 top-level categories; the largest is healthcare & pharma with 8 brands.[1]
Johnson & Johnson has sold or spun off 1 businesses or brands recorded here.
Johnson & Johnson financial history
Headline figures from Johnson & Johnson's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2021–2025.
Revenue moved from $82.6bn to $94.2bn, an average of 2.7% a year (calculated).
Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.
Who owns the shares of Johnson & Johnson
Holders of more than 5% of the voting shares, as listed in Johnson & Johnson's proxy statement filed 11 March 2026. Shareholdings change daily; this is the position the filing reports.
Holder
Shares
Share of class
The Vanguard Group
243,455,135
10.1%
BlackRock, Inc.
186,308,341
7.7%
State Street Corporation
132,996,283
5.5%
Everything Johnson & Johnson owns
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Johnson & Johnson separated its consumer health business as Kenvue, which listed in May 2023 and was fully split off through an exchange offer completed on 23 August 2023. Tylenol, Band-Aid, Listerine, Neutrogena and Johnson's Baby all moved to the new company.
Johnson & Johnson controlled these 13 brands in the past. Each row shows when the ownership ended and who holds the brand now, so a page that once said Johnson & Johnson owned it still shows why it no longer does.
Brandtree needs to remember this choice and does not set any other cookie unless you accept.
If you choose “Accept all”, we also use Google Analytics cookies to count visits and see which pages help, so we can improve the site.
If you choose “Accept required”, no analytics cookie is set. Google Analytics still receives a cookieless ping with the page address and your IP address. No advertising is used either way. Privacy policy